Complementary Elements to the Pathogenesis, Early Detection and Second Line Antihormonal Therapy of Prostate Cancer

Kullmann, Tamás

doi:10.31083/j.jomh1807155

Cited by 3 publications

(3 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Administration of the second line antihormonal agents is recommended until clinical or radiological progression. Or, in a small set of patients of our single centre, patients whose treatment was stopped at PSA progression did not have a worse prognosis than those treated several months longer until clinical or radiological progression [19]. The same antiandrogenic drug was reintroduced to some patients after progression under second line chemotherapy by cabazitaxel.…”

Section: Discussionmentioning

confidence: 95%

Primary Mosaic Neuroendocrine-/Adenocarcinoma of The Prostate: Clinical and Histological Description

Almási,

Kránitz,

Kullmann

2023

Preprint

View full text Add to dashboard Cite

Background: Mosaic cancers are composed of two or several genetically different cell populations. Mosaicism has been considered to be rare among malignancies, with the exception of the germ cell tumours. Although it has been described that neuroendocrine foci might be present within adenocarcinomas of the prostate, this was meant for advanced stage diseases and the clinical relevance of the histological finding has not been clarified. Patients and methods: We recall a single centre cohort of patients with neuroendocrine cancer of the prostate. We show for the first time histological images of a primary mosaic neuroendocrine/adenocarcinoma of the prostate. Results: Contrarily to the general assumption of a rare disease with poor prognosis, the clinical incidence was found to be 2%, being 50 fold higher than the earlier data. During the follow-up the overall survival of some metastatic patients reached several years. The particularity of patients with favourable outcome was the parallel elevation of PSA and NSE. They received anticancer treatments in an alternating way directed according to the tumour marker that was actually in rise. Histological images of primary mosaic prostate cancers are shown. A model explaining the development of mosaic cancers is presented. Conclusion: Mosaic neuroendocrine-/adenocarcinoma of the prostate is underdiagnosed and its prognosis is underestimated.

show abstract

Section: Discussionmentioning

confidence: 95%

Primary Mosaic Neuroendocrine-/Adenocarcinoma of The Prostate: Clinical and Histological Description

Almási,

Kránitz,

Kullmann

2023

Preprint

View full text Add to dashboard Cite

show abstract

“…Administration of the second line antihormonal agents is recommended until clinical or radiological progression. Or, in a small set of patients of our single centre, patients whose treatment was stopped at PSA progression did not have a worse prognosis than those treated several months longer until clinical or radiological progression [17]. The same antihormonal drug was reintroduced to some patients after progression under second line chemotherapy by cabazitaxel.…”

Section: Discussionmentioning

confidence: 95%

Mosaic Neuroendocrine-/Adenocarcinoma of the Prostate: Clinical and Histological Description

Almási,

Kránitz,

Kullmann

2023

Preprint

View full text Add to dashboard Cite

Background: Mosaic cancers are composed of two or several genetically different cell populations. Mosaicism has been considered to be rare among malignancies, with the exception of the germ cell tumours. Although it has been described that neuroendocrine foci may be present within an adenocarcinoma of the prostate, this was ment for advanced stage disease and the clinical relevance of the histological finding has not been clarified. Patients and methods: We recently published the analysis of a small cohort of patients who had neuroendocrine cancer of the prostate. Contrarily to the general assumption of a rare disease with poor prognosis, the incidence was found to be 2%, being 50 fold higher than the earlier data. During the follow-up the overall survival of some metastatic patients reached several years. The particularity of patients with favourable outcome was the parallel elevation of PSA and NSE. They received anticancer treatments in an alternating way directed according to the tumour marker that was in rise. The aim of this paper is to show the pathological background of our clinical observations. Results: Histological images of de novo mosaic prostate cancers are shown. A model explaining the development of mosaic prostate cancers is presented. The hypothesis of mosaicism within adenocarcinomas is formulated in addition. Conclusion: Mosaic neuroendocrine-/adenocarcinoma of the prostate is underestimated regarding its incidence as well as its prognosis.

show abstract

“…Previous research indicates that ~10% of newly diagnosed patients have metastatic lesions which aggravates PC progression [2,3]. Prognoses of late stage and metastatic PC patients is challenging despite the recent global efforts of identifying novel treatment strategies [1,4]. Therapeutic compounds targeting the cellular pathways are therefore important.…”

Section: Introductionmentioning

confidence: 99%

Luteoloside inhibiting the prostate cancer cells growth and promoting the tumor cells autophagy through AKT/mTOR pathway

2023

Journal of Men's Health

View full text Add to dashboard Cite

Prostate cancer (PC) is one of the prevalent tumors in men causing higher mortality. Luteoloside has been discovered for suppressive role into the progression of some cancers. However, the Luteoloside’s regulatory functions regarding PC progression are not well understood. This study is thus designed to investigate the Luteoloside impact on PC progression. In this work, it was demonstrated that the PC cell proliferation was gradually inhibited with the increasing Luteoloside dose (0, 20, 40, 80 µM). Luteoloside also enhanced the PC cell apoptosis. It promoted the autophagy in PC through increasing microtubule-associated protein light chain (LC) 3II/LC3I levels and decreasing p62 levels. Moreover, the Luteoloside reduced phosphorylated-protein kinase B (p-AKT)/AKT and phosphorylated-mechanistic target of rapamycin (p-mTOR)/mTOR levels, indicating that it retarded the AKT/mTOR pathway. In conclusion, the Luteoloside inhibited PC cells growth and promoted tumor cells autophagy through AKT/mTOR pathway. This discovery suggested the Luteoloside as a potential drug in treating PC.

show abstract

Complementary Elements to the Pathogenesis, Early Detection and Second Line Antihormonal Therapy of Prostate Cancer

Cited by 3 publications

References 6 publications

Primary Mosaic Neuroendocrine-/Adenocarcinoma of The Prostate: Clinical and Histological Description

Primary Mosaic Neuroendocrine-/Adenocarcinoma of The Prostate: Clinical and Histological Description

Mosaic Neuroendocrine-/Adenocarcinoma of the Prostate: Clinical and Histological Description

Luteoloside inhibiting the prostate cancer cells growth and promoting the tumor cells autophagy through AKT/mTOR pathway

Contact Info

Product

Resources

About